TGFB1 and chronic kidney disease: Bortezomib, a proteasome inhibitor, is used to prevent the production of alloantibody in the treatment of antibody‐mediated rejection (ABMR) through the induction of plasma cells apoptosis.17 It was also reported that could alleviate the fibrosis of skin, lung and CKD stimulated by TGF‐β.18, 19 However, the effect of Bortezomib in the treatment of allograft kidney interstitial fibrosis caused by EMT still remain to be determined.